News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Time is running out to submit your abstract for the EGFR Summit – EGFR Resisters Research Summit
Oct 14, 2024, 18:04

Time is running out to submit your abstract for the EGFR Summit – EGFR Resisters Research Summit

EGFR Resisters Research Summit shared a post on X:

“TIME IS RUNNING OUT to submit your abstract for the EGFR Summit!

Spots Are Filling Up Quickly – Register today.”

Lung Cancer EGFR Summit

 

cancer cancer awareness cancer care EGFR EGFR Resisters Research Summit EGFR Summit fight against cancer Global fight against cancer OncoDaily Oncology
Special Coverage
Blog
Oct 14, 2024, 18:04
Time is running out to submit your abstract for the EGFR Summit - EGFR Resisters Research Summit
Blog
Oct 14, 2024, 17:58
Melvin Chua: Reinventing the Wheel for Radiotherapy in NPC
Blog
Oct 14, 2024, 17:49
You don’t need the world’s permission to aim high and succeed - Bishal Gyawali about John Jumper's Nobel Prize
Blog
Oct 14, 2024, 17:46
Princella Seripenah: Keep pushing boundaries, breaking stereotypes and creating change
Blog
Oct 14, 2024, 17:42
Akshaya Keerti: Ponsegromab - A New Hope for Managing Cancer Cachexia
Blog
Oct 14, 2024, 17:12
Gianmarco Ricagno: Feeling inspired and energized after the Young2Young conference
Blog
Oct 14, 2024, 17:03
Guiding oncologists in aggressive cancer treatments: App by Vall d'Herbon
Blog
Oct 14, 2024, 16:58
Do we need allogeneic HSCT consolidation after CD19 CAR T therapy for pediatric ALL? - COSTEM Congress
Blog
Oct 14, 2024, 16:54
Experienced financial toxicity among long-term cancer survivors
Blog
Oct 14, 2024, 16:53
Jean T. Stennett Joins Sylvester as Assistant VP of Research Operations
Opinion
Oct 14, 2024, 16:51
Ana Glembotsky: A new RUNX1 hotspot mutation in FPD/AML
Blog
Oct 14, 2024, 16:46
Raul Cordoba: End points in clinical trials in diffuse large B-cell lymphoma